Psychedelic Treatment for Eating Disorders

Lab scientists examining a green bottle of substance. Psychedelics Being Studied for Eating Disorder Treatment.

Verywell / Laura Porter

Unlike most other mental health disorders that can be treated successfully by medication, eating disorders have not been found to be as responsive to traditional psychiatric medicines. Anorexia nervosa has one of the highest mortality rates of any psychiatric illness, and there are few effective psychological treatments and no effective psychiatric medications for the illness.

Even for those disorders such as anxiety and depression for which psychiatric medications exist, the development of new traditional psychopharmacology agents has slowed.

To expand the arsenal of treatments for various psychological disorders, some researchers are now looking at psychedelic medicines as a treatment alternative. And most recently, researchers have begun to examine some of these as potential treatments for eating disorders.

What Are Psychedelics?

Psychedelics, sometimes referred to as hallucinogens, are substances that alter perception, mood, and cognitive processes. They can cause hallucinations: seeing or hearing things that are not real. Psychedelics can occur naturally in trees, plants, and fungi or can be manufactured in laboratories.

A Brief History

The use of hallucinogenic plant medicines in ancient indigenous populations predates written history. LSD, or lysergic acid diethylamide, is a hallucinogenic drug that was first synthesized by a Swiss scientist in the 1930s. Psychedelics were studied as treatments for mental disorders in the 1950s and more than 1000 clinical papers were published in the 1950s and early 1960s.

However, in the late 1960s LSD and marijuana (which is sometimes classified as a hallucinogen) were embraced by youth protesting the Vietnam War and were consequently scapegoated by the mainstream culture as contributing to the corruption of youth.

In reaction, strict laws were passed to prevent their use. The Controlled Substances Act of 1970 placed LSD and other psychedelics known at the time onto Schedule 1, the most restrictive category of drugs. This classification made them virtually impossible to study clinically and effectively ended any significant research into the pharmacology and medical value of psychedelics for more than three decades.

After a lull of several decades, changes in political attitudes and advances in science and technology allowed research to begin again on psychedelics in the 1990s. Most recently, there has been a renewed interest in their use for psychiatric illnesses and studies are once again underway.

How Might Psychedelics Help People with Psychiatric Disorders?

The exact mechanisms of action of psychedelics are not fully understood, but it is theorized that they significantly reduce activity in the brain’s default mode network (DMN). The DMN are the habitual pathways of communication between brain regions. Just like on a snow-covered hill, we tend to follow the tracks that are already there. Over time, it becomes difficult to take any path other than the ones already established.

The DMN appears to be particularly overactive in certain mental health conditions including depression, anxiety, and OCD. By reducing activity in the DMN, psychedelics may provide a break from deeply ingrained psychological patterns and allow for the setting of new tracks. They may increase brain neuroplasticity and creativity.

How does this apply to eating disorders? Cognitive flexibility is impaired in people with anorexia nervosa, which may stem from an overactive DMN. Hence, researchers hypothesize that psychedelics may be an appropriate treatment method.

Press Play for Advice On Treating Emotional Pain

Hosted by Editor-in-Chief and therapist Amy Morin, LCSW, this episode of The Verywell Mind Podcast, featuring psychologist Brian Pilecki, shares how psychedelics can be used to treat emotional pain. Click below to listen now.

Follow Now: Apple Podcasts / Spotify / Google Podcasts / RSS

How are Psychedelics Used in Psychiatric Treatment?

To date, there are only a few systematic studies of treatment models involving psychedelic administration and studies of psychedelic treatment remain in their infancy. What we do seem to know is that psychological support is an important element of treatment with psychedelics. This is referred to as psychedelic-assisted psychotherapy.

The psychological portion of psychedelic medicine usually includes three essential components: preparatory sessions before the drug administration, psychological support during the psychedelic trip, and integration sessions following the dosing session.

It is in these integration sessions that patients solidify insights gained and identify action plans.

Psychedelics are considered relatively safe and, unlike opiates and stimulants, they do not lead to chemical addiction or dependence. Psychedelic assisted psychotherapy differs from conventional psychiatric treatment in that rather than correcting neurochemical dysfunctions in the brain on a daily basis as most traditional psychiatric medicines do, psychedelic-assisted psychotherapy causes modifications in brain functioning and conscious experience. This in turn can lead to meaningful experiences that create emotional, cognitive, and behavioral changes.

Psychedelics and Their Potential for Treating Eating Disorders

Four particular psychedelics have been the subject of most of the recent psychiatric research and have been or are being investigated in terms of eating disorders—Ketamine, MDMA, Psilocybin, and Ayahuasca.

Ketamine

Ketamine has been used in higher dosages as an anesthetic for decades. In lower dosages, it can temporarily modify consciousness. It has been studied for the treatment of depression, obsessive-compulsive disorder, and post-traumatic stress disorder. Over several decades, research has shown that ketamine has antidepressive properties.

Because it is already an approved medication, it has been incorporated more readily into the treatment of psychiatric disorders via off-label use. Ketamine infusion therapy involves the administration of a single infusion or a series of infusions for the management of psychiatric disorders.

Esketamine nasal spray, a derivative of ketamine, has been separately approved by the FDA for treatment-resistant depression. Trials of ketamine-assisted psychotherapy are also underway and may increase the effectiveness of the treatment. Ketamine may not have been investigated specifically for eating disorders yet, but patients with depression may already be accessing it.

MDMA

MDMA is MethylenodioxyMetamphetamine is commonly confused with the street drug “ecstasy” (also known as “molly”). However, these illegal products are often substitutes that contain no actual MDMA, and may contain only substitutes.

MDMA has been designated a breakthrough therapy for PTSD by FDA, a status that can lead to expedited approval. Therapeutic results with severe treatment-resistant PTSD patients were significant with approximately 70% of participants no longer qualifying for the diagnosis 12 months following treatment.

Currently underway is an open-label, multi-site Phase 2 study of the safety and feasibility of MDMA-assisted psychotherapy for eating disorders. This is a multi-site study of individuals with anorexia nervosa restricting subtype and binge-eating disorder. The study is taking place at three sites including Vancouver, Canada, Toronto, Canada, and Denver, Colorado.

Psilocybin

Psilocybin is the active ingredient in what are commonly known as “magic mushrooms”. Psilocybin has been studied in patients with depression, anxiety, obsessive compulsive disorder, and addiction. Psilocybin received a breakthrough designation from the FDA for individuals with treatment-refractory depression. In 2020 Oregon became the first state in the country to legalize psilocybin for medical use.

A current study is underway to explore the safety, tolerability, and efficacy of psilocybin for individuals with anorexia nervosa.

Participants will receive a single 25 mg dose of psilocybin along with psychotherapeutic support, which includes preparation and integration sessions surrounding the experience. This trial is being conducted in Baltimore, Maryland and San Diego, California.

Researcher and psilocybin therapist Stephanie Knatz Peck, Ph.D. who was involved in a psilocybin-assisted trial for the treatment of depression and now is working on the anorexia study said this:

"Psilocybin-assisted therapy holds tremendous promise for mental health. Studies evaluating the therapy for depression, end-of-life anxiety, and smoking cessation have produced impressively robust improvements in symptoms and more studies are underway evaluating the treatment for other mental illnesses.

We are excited to evaluate the usefulness of this therapy for anorexia nervosa, particularly given the lack of good treatment options currently available. Our UCSD study is a small pilot study evaluating the safety, tolerability, and initial efficacy of psilocybin-assisted therapy for adults with anorexia nervosa." 

Ayahuasca

Ayahuasca is a traditional Amazonian psychoactive plant-based tea used in rituals by indigenous leaders and as part of religious ceremonies. Its use has spread to other parts of the world. People who drink ayahuasca usually report powerful visions and mystical experiences. It is usually drunk in traditional-style shamanic, religious ceremonies.

Participants typically drink a small glass of the tea in a ceremony that can last between four to eight hours. They may experience nausea, vomiting, sweating, and altered states of consciousness. Research on ayahuasca shows it might be helpful for mental health problems including depression, anxiety, and addictions.

People with eating disorder histories have been participating in ayahuasca ceremonies. One retrospective study of participants by La France and colleagues concluded that “ceremonial ayahuasca drinking may have promise as an alternative treatment.” The majority of participants surveyed reported significant insights about their illness and believed that ayahuasca has led to reductions in eating disorder symptoms. They also reported that the experience nurtured their self-compassion.

A Word From Verywell

It should be clarified that the evidence for psychedelics for the treatment of psychiatric disorders does not involve their recreational use. When used properly with psychotherapy, they can be a tool to help people change the way they look at themselves and the world. Participants who use psychedelics recreationally without the therapy integration are not likely to experience the same benefits. If you are considering whether psychedelic-assisted therapy may be helpful to you, please consult with a health professional.

Was this page helpful?
23 Sources
Verywell Mind uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.
  1. Bulik CM, Flatt R, Abbaspour A, Carroll I. Reconceptualizing anorexia nervosa. Psychiatry and Clinical Neurosciences. 2019;73(9):518-525. doi:10.1111/pcn.12857

  2. Schenberg EE. Psychedelic-assisted psychotherapy: A paradigm shift in psychiatric research and development. Frontiers in Pharmacology. 2018;9(733). doi:10.3389/fphar.2018.00733

  3. Breeksema JJ, Niemeijer AR, Krediet E, Vermetten E, Schoevers RA. Psychedelic treatments for psychiatric disorders: A systematic review and thematic synthesis of patient experiences in qualitative studies. CNS Drugs. 2020;34(9):925-946. doi:10.1007/s40263-020-00748-y

  4. Haijen ECHM, Kaelen M, Roseman L, et al. Predicting responses to psychedelics: A prospective study. Frontiers in Pharmacology. 2018;9. doi:10.3389/fphar.2018.00897

  5. Smith DE. The role of the Journal of Psychedelic Drugs in the evolution of psychedelic medicine. Journal of Psychoactive Drugs. 2019;51(2):98-101. doi:10.1080/02791072.2019.1589607

  6. Vitiello M. The war on drugs: Moral panic and excessive sentences. SSRN Electronic Journal. 2020;69. doi:10.2139/ssrn.3689183

  7. Nichols DE. Psychedelics. Pharmacological Reviews. 2016;68(2):264-355. doi:10.1124/pr.115.011478

  8. Carhart-Harris RL. How do psychedelics work? Current Opinion in Psychiatry. 2018;32(1):1. doi:10.1097/yco.0000000000000467 

  9. Nichols DE, Johnson MW, Nichols CD. Psychedelics as medicines: An emerging new paradigm. Clinical pharmacology and therapeutics. 2017;101(2):209-219. doi:10.1002/cpt.557

  10. Foldi CJ, Liknaitzky P, Williams M, Oldfield BJ. Rethinking therapeutic strategies for anorexia nervosa: Insights from psychedelic medicine and animal models. Frontiers in Neuroscience. 2020;14. doi:10.3389/fnins.2020.00043

  11. Hosanagar A, Cusimano J, Radhakrishnan R. Therapeutic potential of psychedelics in treatment of psychiatric disorders, part 2. The Journal of Clinical Psychiatry. 2021;82(3). doi:10.4088/jcp.20ac13787

  12. Gründer G. Psychedelics: A new treatment paradigm in psychiatry? Pharmacopsychiatry. 2021;54(04):149-150. doi:10.1055/a-1520-5020

  13. Garcia-Romeu A, Richards WA. Current perspectives on psychedelic therapy: Use of serotonergic hallucinogens in clinical interventions. International Review of Psychiatry. 2018;30(4):291-316. doi:10.1080/09540261.2018.1486289 131.

  14. Martinotti G, Chiappini S, Pettorruso M, et al. Therapeutic potentials of ketamine and Esketamine in obsessive–compulsive disorder (OCD), substance use disorders (SUD) and eating disorders (ED): A review of the current literature. Brain Sciences. 2021;11(7):856. doi:10.3390/brainsci11070856

  15. Edland-Gryt M, Sandberg S, Pedersen W. From ecstasy to MDMA: Recreational drug use, symbolic boundaries, and drug trends. International Journal of Drug Policy. 2017;50:1-8. doi:10.1016/j.drugpo.2017.07.030

  16. Mithoefer MC, Feduccia AA, Jerome L, et al. MDMA-assisted psychotherapy for treatment of PTSD: Study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials. Psychopharmacology. 2019;236(9). doi:10.1007/s00213-019-05249-5

  17. Multidisciplinary association for psychedelic Studies. An open-label, multi-site phase 2 study of the safety and feasibility of MDMA-assisted psychotherapy for eating disorders. clinicaltrials.gov. Published August 9, 2021. https://clinicaltrials.gov/ct2/show/NCT04454684

  18. Daniel J, Haberman M. Clinical potential of psilocybin as a treatment for mental health conditions. Mental Health Clinician. 2017;7(1):24-28. doi:10.9740/mhc.2017.01.024

  19. Reiff CM, Richman EE, Nemeroff CB, et al. Psychedelics and psychedelic-assisted psychotherapy. American Journal of Psychiatry. 2020;177(5):appi.ajp.2019.1. doi:10.1176/appi.ajp.2019.19010035

  20. Holoyda B. The rebirth of psychedelic psychiatry: Recent research suggests psychedelic agents might help treat anxiety, depression, other disorders. Current Psychiatry. 2021;20(1):12-20. doi:10.12788/cp.0079

  21. UCSD. UCSD Anorexia Trial: Evaluation of Psilocybin in Anorexia Nervosa: Safety and Efficacy. clinicaltrials.ucsd.edu. Published June 2021. https://clinicaltrials.ucsd.edu/trial/NCT04661514

  22. Renelli M, Fletcher J, Tupper KW, Files N, Loizaga-Velder A, Lafrance A. An exploratory study of experiences with conventional eating disorder treatment and ceremonial ayahuasca for the healing of eating disorders. Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity. 2018;(2). doi:10.1007/s40519-018-0619-6

  23. Lafrance A, Loizaga-Velder A, Fletcher J, Renelli M, Files N, Tupper KW. Nourishing the spirit: Exploratory research on Ayahuasca experiences along the continuum of recovery from eating disorders. Journal of Psychoactive Drugs. 2017;49(5):427-435. doi:10.1080/02791072.2017.1361559